[{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"LIV-2008","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chiome Bioscience \/ Henlius","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Henlius"}]

Find Clinical Drug Pipeline Developments & Deals by Chiome Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.

                          Brand Name : LIV-2008

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 14, 2021

                          Lead Product(s) : LIV-2008

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Henlius

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank